Traders should monitor the April 27 webcast for signals on tovecimig’s efficacy and safety, which could drive meaningful volatility. A positive outcome may catalyze re-rating potential in this small-cap oncology stock, while negative or ambiguous data could lead to downside risk.
Price Chart
Executive Summary
Compass Therapeutics (CMPX) will host a webcast on April 27, 2026, to present topline secondary endpoint data from its Phase 2/3 COMPANION-002 trial of tovecimig in combination with paclitaxel for advanced biliary tract cancer. This data readout is a key near-term catalyst for the company, as it could support further development or regulatory discussions for a novel bispecific antibody in a high-unmet-need indication.
Key Facts
- Compass Therapeutics will present topline secondary endpoints from the Phase 2/3 COMPANION-002 trial on April 27, 2026.
- The trial evaluates tovecimig (a DLL4 x VEGF-A bispecific antibody) plus paclitaxel in advanced biliary tract cancer (BTC).
- Data will be shared via webcast at 8:00am ET, with replay available for 90 days.
- No primary endpoint results or efficacy/safety data are disclosed in this announcement — only the timing of the upcoming presentation.
Financial Impact
No financial impact until data is released; potential for significant stock movement post-readout depending on results.
Risk Factors
- Secondary endpoints are less definitive than primary endpoints and may not support regulatory approval.
- Bispecific antibodies face competitive and safety challenges; any toxicity signals could weigh on sentiment.
- CMPX is a clinical-stage company with no approved products — valuation is entirely dependent on pipeline execution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281064 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 3d ago | Press Release | $0.7697 | awaiting T+20 | — | $0.7682 (−0.19%) |
Sep 22, 2026 5w ago | 8-K | $1.24 $0.8330 | ▲ +32.82% | ▲ +32.26% | $0.7682 (+38.05%) |
Aug 21, 2026 9w ago | Institutional Cluster | $2.40 $1.90 | ▼ −20.83% | ▼ −20.55% | $0.7682 (−67.99%) |
Aug 6, 2026 11w ago | 8-K | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7682 (−61.40%) |
Aug 6, 2026 11w ago | Press Release | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7682 (−61.40%) |
Jul 17, 2026 14w ago | Press Release | $2.05 $2.25 | ▲ +9.76% | ▲ +5.31% | $0.7682 (−62.53%) |
Jul 1, 2026 16w ago | 8-K | $2.27 $1.94 | ▼ −14.54% | ▼ −14.12% | $0.7682 (−66.16%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.03 $2.33 | ▲ +14.78% | ▲ +13.00% | $0.7682 (−62.16%) |
May 21, 2026 22w ago | Press Release | $2.07 $2.09 | ▲ +0.72% | ▲ +2.14% | $0.7682 (−62.89%) |
May 5, 2026 25w ago | 8-K | $1.95 $2.08 | ▲ +6.67% | ▲ +1.71% | $0.7682 (−60.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers